Myriad Genetics, Inc. has launched a new educational website called "Know More Sooner," aimed at providing detailed information about reproductive and prenatal genetic testing. The site seeks to ...
UBS initiated coverage of Myriad Genetics (MYGN) with a Neutral rating and $18 price target The analyst believes Myriad’s growth profile has improved versus historical trends, but says GeneSight ...
Michael Ryskin, an analyst from Bank of America Securities, maintained the Sell rating on Myriad Genetics (MYGN – Research Report). The associated price target remains the same with $13.00.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback